Hematology

Genetically predicted anemia may be casually linked to an increased risk of asthma, suggesting its role in the chronic lung disease's development.

Late-breaking data from EHA 2024 demonstrated a high overall response rate and favorable safety across a range of sHLH patients treated with ELA026.

Bitopertin achieves significant reductions in PPIX versus placebo in patients with erythropoietic protoporphyria.

Long-term Phase 2 data demonstrate KP104's potential as an optimal first-line monotherapy for PNH.

In the ENERGIZE trial, oral mitapivat achieved meaningful improvements in symptoms of anemia in patients with non-transfusion-dependent thalassemia.

The CRISPR-based gene therapy demonstrated durable effects on SCD and TDT, with the longest follow-up extending past 5 years.

Phase 1/2 EdiTHAL trial data shows reni-cell remained well-tolerated and displayed promising efficacy for patients with TDT.

Phase 1/2/3 trial data show the investigational gene-editing medicine has been well-tolerated, with encouraging efficacy, for people living with SCD.

Blood loss due to whole blood donation and menstruation were the two most important determinants for ferritin and hemoglobin levels in female blood donors.

Based on the 36-item Short Form Survey questionnaire, adults with SCD in France report low physical and mental health summary scores.

Hydroxyurea treatment may impact seminal fluid levels and ovarian reserves in male and female patients with sickle cell disease.

A higher serum ferritin threshold could lead to better diagnosis and treatment of more women with iron deficiency.

Knowledge, attitudes, and practices remain relevant for disease management among patients with anemia.

High-impact chronic pain is a severely affected subgroup in SCD and is associated with greater pain burden and worse health outcomes.

A lower FACIT-Fatigue score, indicating higher fatigue was independently associated with female sex, a high BMI, a high stress level, and poor sleep quality.

Daprodustat 25-30 mg was linked to the most significant rise in serum hemoglobin and reduced serum ferritin levels.

Topline results from the randomized, placebo-controlled Phase 3 clinical trial demonstrated a statistically significant 87% reduction in IgG4-RD flares.

Our May 2024 month-in-review for hematology focuses on important FDA updates, new anemia data from ERA 2024, and the latest imaging modalities.

A quality improvement initiative exhibited a sustained increase in transcranial Doppler screening rates over an 8-year intervention period.

Diagnostic tests for anemia etiology are infrequently ordered, leading to a significant majority of patients with CKD receiving inadequate treatment.

Iron administration did not increase the mortality risk of hemodialysis patients with cancer, but the safety of increasing ESA doses was not confirmed.

An analysis of more than 800 IgAN patients treated from 2002-2021 provides an overview of factors associated with anemia as well as its impact on prognosis.

Data from ERA 24 builds on previous research examining the effect of SGLT2 inhibitors on hemoglobin levels among patients with chronic kidney disease.

The smartphone app demonstrated higher accuracy, sensitivity, and specificity in patients with severe anemia than those with moderate anemia.

Retrospective data suggest the off-label use of IVIg could be helpful in the management of severe autoimmune hemolytic anemia.